Compare Pfizer Inc (PFE) vs AT&T Inc. (T) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

AT&T (T) trades at $22.26, up 2.13% with a bullish technical signal despite mixed moving averages. The stock shows strong fundamentals with a low P/E of 7.39, robust profitability margins (net margin 16.94%), and consistent earnings beats in recent quarters. Recent cash flow improvement to $15.12B in 2025 and declining debt-to-asset ratio to 32.59% in 2024 signal financial health. The company faces competitive pressures in telecom but benefits from fiber expansion and stable wireless pricing.

Outlook remains positive with analyst consensus target of $25.61 offering 15% upside. Key opportunities include dividend yield support and fiber growth, while risks involve intense telecom competition and potential earnings volatility. Wall Street sentiment is cautiously optimistic with 41% buy ratings, though technical indicators show some overbought conditions near-term.